| | | Novo Nordisk's Ozempic gets FDA approval for kidney disease
Jan. 28, 2025 3:15 PM ET
By: Val Brickates Kennedy, SA News Editor
 hapabapa
Novo Nordisk ( NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
The Danish drugmaker said the approval makes semaglutide the first GLP-1 RA drug approved for the indication. Semaglutide is also approved for weight loss and is marketed for that indication under the name Wegovy.
In 2020, Ozempic was granted additional approval to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.
Semaglutide's main competitor in the GLP-1 RA therapy market is Eli Lilly's ( LLY) tirzepatide, which is marketed for diabetes as Mounjaro and for weight loss as Zepbound.
Other companies working on GLP-1 drugs include AstraZeneca ( AZN), Amgen ( AMGN), Pfizer ( PFE), Roche ( OTCQX:RHHBY), Altimmune ( ALT), Viking Therapeutics ( VKTX), Zealand Pharma ( OTCPK:ZLDPF), Terns Pharmaceuticals ( TERN) and Structure Therapeutics ( GPCR). |
|
